A retrospective multicenter study with 101 patients, including, but not limited to, melanoma patients, has suggested better outcomes to immune checkpoint blockade for patients with alterations in the tumor suppressor gene LRP1b (low-density lipoprotein receptor-related protein 1b). Here, LRP1B is linked to melanoma.